Review: taking Celexa and Lamictal xr together


Summary

Drug interactions are reported among people who take Celexa and Lamictal xr together. This review analyzes the effectiveness and drug interactions between Celexa and Lamictal xr. It is created by eHealthMe based on reports of 2,611 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Celexa

Celexa has active ingredients of citalopram hydrobromide. It is often used in depression. (latest outcomes from Celexa 39,893 users)

Lamictal Xr

Lamictal xr has active ingredients of lamotrigine. It is often used in epilepsy. (latest outcomes from Lamictal xr 980 users)

On Sep, 15, 2016

2,611 people who take Celexa, Lamictal Xr are studied.


Number of reports submitted per year:

Celexa and Lamictal xr drug interactions.

Drug effectiveness over time:

Celexa:
  • < 1 month: 18.0% - (2 of 11 people)
  • 1 - 6 months: 20.0% - (5 of 24 people)
  • 6 - 12 months: 22.0% - (6 of 27 people)
  • 1 - 2 years: 21.0% - (7 of 32 people)
  • 2 - 5 years: 44.0% - (30 of 68 people)
  • 5 - 10 years: 44.0% - (15 of 34 people)
  • 10+ years: 30.0% - (3 of 10 people)
  • not specified: 40.0% - (2 of 5 people)
Lamictal Xr:
  • < 1 month: 10.0% - (1 of 10 people)
  • 1 - 6 months: 38.0% - (14 of 36 people)
  • 6 - 12 months: 33.0% - (9 of 27 people)
  • 1 - 2 years: 39.0% - (15 of 38 people)
  • 2 - 5 years: 59.0% - (35 of 59 people)
  • 5 - 10 years: 77.0% - (24 of 31 people)
  • 10+ years: 85.0% - (12 of 14 people)
  • not specified: 100.0% - (3 of 3 people)

Drug effectiveness by gender:

Celexa:
  • female: 31.0% - (51 of 161 people)
  • male: 38.0% - (19 of 50 people)
Lamictal Xr:
  • female: 52.0% - (86 of 165 people)
  • male: 50.0% - (27 of 53 people)

Drug effectiveness by age:

Celexa:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 29.0% - (5 of 17 people)
  • 20-29: 28.0% - (8 of 28 people)
  • 30-39: 25.0% - (17 of 68 people)
  • 40-49: 40.0% - (20 of 50 people)
  • 50-59: 40.0% - (13 of 32 people)
  • 60+: 43.0% - (7 of 16 people)
Lamictal Xr:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 52.0% - (10 of 19 people)
  • 20-29: 46.0% - (14 of 30 people)
  • 30-39: 55.0% - (38 of 69 people)
  • 40-49: 48.0% - (25 of 52 people)
  • 50-59: 58.0% - (18 of 31 people)
  • 60+: 47.0% - (8 of 17 people)

Most common drug interactions over time *:

< 1 month:
  • drug rash with eosinophilia and systemic symptoms
  • pyrexia
  • platelet count decreased
  • haemoglobin decreased
  • nerve injury
  • neutropenic sepsis
  • rash erythematous
  • vomiting
  • neutrophil count decreased
  • somnolence
1 - 6 months:
  • rash
  • asthenia
  • fatigue
  • blood creatine phosphokinase increased
  • facial paresis
  • myopathy
  • stevens-johnson syndrome
  • convulsion
  • fall
  • headache
6 - 12 months:
  • foetal exposure during pregnancy
  • respiratory disorder neonatal
  • anomaly of external ear congenital
  • external auditory canal atresia
  • somnolence
  • agitation neonatal
  • feeding disorder neonatal
  • neonatal infection
  • rash
  • general physical health deterioration
1 - 2 years:
  • dizziness
  • drug toxicity
  • encephalitis
  • fatigue
  • palpitations
  • depression
  • malaise
  • thyroiditis
  • angioedema
  • deformity
2 - 5 years:
  • diabetes mellitus
  • short-term memory loss
  • neuropathy peripheral
  • nausea
  • anxiety
  • dry mouth
  • depression
  • folliculitis
  • heart attack
  • restlessness
5 - 10 years:
  • convulsion
  • dizziness
  • headache
  • memory impairment
  • anxiety
  • balance disorder
  • cognitive disorder
  • dementia
  • drug ineffective
  • fatigue
10+ years:
  • acanthosis nigricans
  • cerebral palsy
  • dystonia
  • long-term memory loss
  • muscle spasticity
  • short-term memory loss
  • psychotic disorder
  • fatigue
  • hallucination, visual
  • dexamethasone suppression test positive
not specified:
  • completed suicide
  • depression
  • anxiety
  • dizziness
  • insomnia
  • nausea
  • somnolence
  • drug ineffective
  • fall
  • convulsion

Most common drug interactions by gender *:

female:
  • completed suicide
  • depression
  • dizziness
  • headache
  • anxiety
  • nausea
  • rash
  • fall
  • fatigue
  • insomnia
male:
  • completed suicide
  • somnolence
  • convulsion
  • diabetes mellitus
  • depression
  • vomiting
  • nausea
  • anxiety
  • drug ineffective
  • suicidal ideation

Most common drug interactions by age *:

0-1:
  • foetal exposure during pregnancy
  • respiratory disorder neonatal
  • agitation neonatal
  • anomaly of external ear congenital
  • external auditory canal atresia
  • feeding disorder neonatal
  • neonatal infection
  • somnolence
  • umbilical cord around neck
  • blood triglycerides increased
2-9:
  • rash generalised
  • abnormal behaviour
  • convulsion
  • disinhibition
  • ecchymosis
  • prescribed overdose
  • rash papular
  • stevens johnson syndrome
10-19:
  • completed suicide
  • serotonin syndrome
  • ventricular tachycardia
  • electrocardiogram qrs complex prolonged
  • pyrexia
  • intentional overdose
  • unresponsive to stimuli
  • convulsion
  • acanthosis nigricans
  • cerebral palsy
20-29:
  • tremor
  • vomiting
  • electrocardiogram qt prolonged
  • agitation
  • dizziness
  • electrocardiogram qrs complex prolonged
  • depressed level of consciousness
  • metabolic acidosis
  • nystagmus
  • multiple drug overdose intentional
30-39:
  • completed suicide
  • headache
  • rash
  • nausea
  • vomiting
  • fatigue
  • cardiac arrest
  • dizziness
  • convulsion
  • hypotension
40-49:
  • completed suicide
  • drug rash with eosinophilia and systemic symptoms
  • somnolence
  • headache
  • vomiting
  • nausea
  • suicide attempt
  • nerve injury
  • depression
  • overdose
50-59:
  • completed suicide
  • drug ineffective
  • fall
  • rash
  • depression
  • anxiety
  • dizziness
  • confusional state
  • insomnia
  • fatigue
60+:
  • fall
  • dizziness
  • nausea
  • fatigue
  • convulsion
  • dyspnoea
  • anxiety
  • haemoglobin decreased
  • rash erythematous
  • arthralgia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Celexa and Lamictal xr?

Can you answer these questions?

More questions for: Celexa, Lamictal xr

You may be interested in these reviews

More reviews for: Celexa, Lamictal xr

On eHealthMe, Celexa (citalopram hydrobromide) is often used to treat depression. Lamictal xr (lamotrigine) is often used to treat epilepsy. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.